Legendary investor Warren Buffett once advised, “Be fearful when others are greedy and be greedy when others are fearful.” This sage mantra reverberates through the cavernous halls of Wall Street, reminding investors to seek opportunity amidst tumultuous markets. How might one gauge the tempest within a stock? Enter the Relative Strength Index (RSI), that mystical numerical denotation ranging from 0 to 100, measuring momentum. A stock plunges into the icy depths of oversold territory as its RSI dips beneath 30.

Sharing in the tales of volatility, Xenon Pharmaceuticals Inc (Symbol: XENE) recently meandered into such oversold abyss during Tuesday’s trading session. With an RSI whispering at 29.5, the stock waltzed as low as $41.135 per share, cloaked in an air of despair. In contrast, the S&P 500 ETF (SPY) boasts a more serene RSI at 59.4, a stark juxtaposition to XENE’s forlorn figure. A savvy investor might spy XENE’s RSI of 29.5 as a beacon of hope – a signal that the cacophony of recent sell-offs might be breathing its dying breath, birthing a harbinger of potential buy-side openings. Behold the chart below, narrating the yearlong saga of XENE shares:

Perched upon the peaks and valleys of the chart, XENE’s 52-week odyssey unfolds. The stock’s nadir kisses $27.985 per share, juxtaposed with its zenith of $50.99 – a tumultuous tale culminating in a recent trade at $41.47, a figure echoing with both vulnerability and potential.

---

Free Report: Top 8%+ Dividends (paid monthly)

Discover the whispers of 9 other downtrodden stocks waiting to be embraced »

Further Exploration:

• Embarking on a journey through MDT’s Average Annual Return
• Untangling the intricate web of IMCG’s Options Chain
• Pondering over the enigmatic dance of ACGL’s Insider Buying

The rhythm and rhyme expressed herein reflect the musings and reflections of the author, a solitary voice adrift in the tumultuous sea of finance. These words do not purport to wear the mantle of Nasdaq, Inc.’s sagely counsel.